表紙
市場調查報告書

全球呼吸道融合病毒(RSV)感染疾病治療藥市場:各藥品(Palivizumab,Ribavirin),給藥途徑(口服,注射),流通管道,地區 - 產業分析,市場規模,佔有率,成長,趨勢,預測(2017年∼2025年)

Respiratory Syncytial Virus (RSV) Therapeutics Market (Drugs Type - Palivizumab, Ribavirin; Dosage Form - Oral, Injectable; Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

出版商 Transparency Market Research 商品編碼 635228
出版日期 內容資訊 英文 176 Pages
商品交期: 最快1-2個工作天內
價格
全球呼吸道融合病毒(RSV)感染疾病治療藥市場:各藥品(Palivizumab,Ribavirin),給藥途徑(口服,注射),流通管道,地區 - 產業分析,市場規模,佔有率,成長,趨勢,預測(2017年∼2025年) Respiratory Syncytial Virus (RSV) Therapeutics Market (Drugs Type - Palivizumab, Ribavirin; Dosage Form - Oral, Injectable; Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
出版日期: 2018年04月19日內容資訊: 英文 176 Pages
簡介

本報告提供全球呼吸道融合病毒(RSV)感染疾病治療藥市場調查,市場概要,各藥品、給藥途徑、流通管道、地區的市場趨勢,市場規模的變化與預測,成長要素、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

  • 市場定義和範圍
  • 市場區分
  • 主要的調查目的
  • 調查的重點

第2章 前提條件與調查方法

第3章 摘要整理

第4章 市場概要

  • 簡介
    • 產品概要
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 開發平台分析
  • 流行病學評估
  • 市場分析與預測
    • 收益額的預測
    • 市場預測
  • 主要趨勢

第5章 全球PS病毒感染疾病治療藥市場:各藥品

  • 主要的發現/開發
  • 簡介
  • 市場規模的變化與預測:各藥品
    • Palivizumab
    • Ribavirin
    • 其他
  • 市場魅力分析:各藥品

第6章 全球呼吸道融合病毒(RSV)感染疾病治療藥市場:各給藥途徑

  • 主要的發現/開發
  • 簡介
  • 市場規模的變化與預測:各給藥途徑
    • 口服
    • 注射
    • 其他
  • 市場魅力分析:各給藥途徑

第7章 全球呼吸道融合病毒(RSV)感染疾病治療藥市場:各流通管道

  • 主要的發現/開發
  • 簡介
  • 市場規模的變化與預測:各流通管道
    • 藥妝店、零售藥局
    • 醫院藥局
    • 其他
  • 市場魅力分析:各流通管道

第8章 全球呼吸道融合病毒(RSV)感染疾病治療藥市場:各地區

  • 地區區分
  • 市場規模的變化與預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲
  • 市場魅力分析:各地區

第9章 北美

第10章 歐洲

第11章 亞太地區

第12章 南美

第13章 中東、非洲

第14章 競爭情形

  • 競爭分析
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
  • 企業簡介(詳細內容 - 概要,財務,最新趨勢,策略)
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca plc.
    • Merck 7 Co., Inc.
    • AbbVie, Inc.
    • Valeant Pharmaceuticals International, Inc.
    • GlaxoSmithKline plc.
    • ReViral Ltd.
    • Gilead Sciences, Inc.
    • MEDIVIR AB
    • Teva Pharmaceuticals Industries Ltd.
目錄

Title:
Respiratory Syncytial Virus (RSV) Therapeutics Market (Drugs Type - Palivizumab, Ribavirin; Dosage Form - Oral, Injectable; Distribution Channel - Drug stores and Retail Pharmacies, Hospital Pharmacies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025.

Global Respiratory Syncytial Virus (RSV) Therapeutics Market: Overview

Respiratory syncytial virus infection is highly contagious. It is reported to be the most common cause of pneumonia and bronchiolitis in children as well as adults. According to the Center for Disease and Prevention, around 25-40 of every 100 children exposed to RSV infection for the first time develop signs of bronchiolitis or pneumonia. No approved drugs have been available in the market to treat RSV infection till date, and only prophylaxis drugs have been used. Therefore, several biopharmaceutical companies are investing in research and development in order to develop new drugs and vaccine to treat or prevent the RSV infection.

The global respiratory syncytial virus (RSV) therapeutics market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drugs type, dosage form, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. Additionally, the section comprises competitive matrix and company profiles with business overview in order to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global respiratory syncytial virus (RSV) therapeutics market.

Global Respiratory Syncytial Virus (RSV) Therapeutics Market: Key Segments

Based on drugs type, the global respiratory syncytial virus (RSV) therapeutics market can be segmented into palivizumab, ribavirin, and others. The drug type segments have been analyzed based on type of drug uses to treat RSV infection in the different region. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. According to dosage form, the global respiratory syncytial virus (RSV) therapeutics market can be classified into oral, injectable, and others. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Respiratory Syncytial Virus (RSV) Therapeutics Market: Regional Outlook

In terms of geography, the global respiratory syncytial virus (RSV) therapeutics market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico and Rest of Latin America) and Middle East and Africa (GCC Countries, South Africa, Israel, and Rest of MEA). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the respiratory syncytial virus (RSV) therapeutics market are include F. Hoffmann-La Roche Ltd., AstraZeneca plc, Merck & Co., Inc., AbbVie, Inc., Valeant Pharmaceuticals International, Inc, GlaxoSmithKline plc., ReViral Ltd., Gilead Sciences, Inc., and Teva Pharmaceutical Industries Ltd.

The global respiratory syncytial virus (RSV) therapeutics market has been segmented as follows:

Respiratory Syncytial Virus (RSV) Therapeutics Market, by Drugs Type

  • Palivizumab
  • Ribavirin
  • Others

Respiratory Syncytial Virus (RSV) Therapeutics Market, by Dosage Form

  • Oral
  • Injectable
  • Others

Respiratory Syncytial Virus (RSV) Therapeutics Market, by Distribution Channel

  • Drug Stores and Retail Pharmacies
  • Hospital Pharmacies
  • Others

Respiratory Syncytial Virus (RSV) Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

Table of Contents

Chapter 1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary : Global Respiratory Syncytial Virus (RSV) Therapeutics Market

Chapter 4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Overview
  • 4.2. Market Dynamics
    • 4.2.1. Drivers
    • 4.2.2. Restraints
    • 4.2.3. Opportunities
  • 4.3. Pipeline Analysis - Respiratory Syncytial Virus (RSV) Therapeutics Market
  • 4.4. Epidemiology Assessment - Respiratory Syncytial Virus (RSV) Therapeutics Market
  • 4.5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, 2015-2025
    • 4.5.1. Market Revenue Projection (US$ Mn)
    • 4.5.2. Market Outlook
  • 4.6. Key Trends

Chapter 5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Drugs Type

  • 5.1. Key Findings / Developments
  • 5.2. Introduction & Definition
  • 5.3. Market Value Forecast, by Drugs Type, 2016-2025
    • 5.3.1. Palivizumab
    • 5.3.2. Ribavirin
    • 5.3.3. Others
  • 5.4. Market Attractiveness, by Drugs Type

Chapter 6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Selection Technique

  • 6.1. Key Findings / Developments
  • 6.2. Introduction & Definition
  • 6.3. Market Value and Volume Forecast, by Dosage Form, 2016-2025
    • 6.3.1. Oral
    • 6.3.2. Injectable
    • 6.3.3. Others
  • 6.4. Market Attractiveness, by Dosage Form

Chapter 7. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Distribution Channel

  • 7.1. Key Findings / Developments
  • 7.2. Introduction & Definition
  • 7.3. Market Value and Volume Forecast, by Distribution Channel, 2017-2025
    • 7.3.1. Drug Stores & Retail Pharmacies
    • 7.3.2. Hospital Pharmacies
    • 7.3.3. Others
  • 7.4. Market Attractiveness, by Distribution Channel

Chapter 8. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Geography/Region

  • 8.1. Geographical Representation
  • 8.2. Market Value and Volume Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

Chapter 9. North America Respiratory Syncytial Virus (RSV) Therapeutics Analysis and Forecast

  • 9.1. Market Value Forecast, by Country , 2016-2025
    • 9.1.1. U.S.
    • 9.1.2. Canada
  • 9.2. Market Value Forecast, by Drugs Type, 2016-2025
  • 9.3. Market Value Forecast, by Dosage Form, 2016-2025
  • 9.4. Market Value Forecast, by Distribution Channel, 2016-2025
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Country
    • 9.5.2. By Drugs Type
    • 9.5.3. By Dosage Form
    • 9.5.4. By Distribution Channel
  • 9.6. Key Trends

Chapter 10. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

  • 10.1. Market Value Forecast, by Country , 2017-2025
    • 10.1.1. Germany
    • 10.1.2. France
    • 10.1.3. U.K.
    • 10.1.4. Spain
    • 10.1.5. Italy
    • 10.1.6. Rest of Europe
  • 10.2. Market Value Forecast, by Drugs Type, 2016-2025
  • 10.3. Market Value Forecast, by Dosage Form, 2016-2025
  • 10.4. Market Value Forecast, by Distribution Channel, 2016-2025
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Country
    • 10.5.2. By Drugs Type
    • 10.5.3. By Dosage Form
    • 10.5.4. By Distribution Channel
  • 10.6. Key Trends

Chapter 11. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

  • 11.1. Market Value Forecast, by Country , 2017-2025
    • 11.1.1. China
    • 11.1.2. Japan
    • 11.1.3. India
    • 11.1.4. Australia & New Zealand
    • 11.1.5. Rest of APAC
  • 11.2. Market Value Forecast, by Drugs Type, 2016-2025
  • 11.3. Market Value Forecast, by Dosage Form, 2016-2025
  • 11.4. Market Value Forecast, by Distribution Channel, 2016-2025
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Country
    • 11.5.2. By Drugs Type
    • 11.5.3. By Dosage Form
    • 11.5.4. By Distribution Channel
  • 11.6. Key Trends

Chapter 12. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

  • 12.1. Market Value Forecast, by Country, 2017-2025
    • 12.1.1. Brazil
    • 12.1.2. Mexico
    • 12.1.3. Rest of LATAM
  • 12.2. Market Value Forecast, by Drugs Type, 2016-2025
  • 12.3. Market Value Forecast, by Dosage Form, 2016-2025
  • 12.4. Market Value Forecast, by Distribution Channel, 2016-2025
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Country
    • 12.5.2. By Drugs Type
    • 12.5.3. By Dosage Form
    • 12.5.4. By Distribution Channel
  • 12.6. Key Trends

Chapter 13. Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

  • 13.1. Market Value Forecast, by Country, 2017-2025
    • 13.1.1. GCC Countries
    • 13.1.2. South Africa
    • 13.1.3. Israel
    • 13.1.4. Rest of Middle East & Africa
  • 13.2. Market Value Forecast, by Drugs Type, 2016-2025
  • 13.3. Market Value Forecast, by Dosage Form, 2016-2025
  • 13.4. Market Value Forecast, by Distribution Channel, 2016-2025
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Country
    • 13.5.2. By Drugs Type
    • 13.5.3. By Dosage Form
    • 13.5.4. By Distribution Channel
  • 13.6. Key Trends

Chapter 14. Competition Landscape

  • 14.1. Competition Matrix
    • 14.1.1. Merck & Co., Inc.
    • 14.1.2. F. Hoffmann-La Roche Ltd.
  • 14.2. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 14.2.1. F. Hoffmann-La Roche Ltd. (HQ, Business Segments, Employee Strength)
      • 14.2.1.1. Company Details
      • 14.2.1.2. Company Description
      • 14.2.1.3. Business Overview
      • 14.2.1.4. SWOT Analysis
      • 14.2.1.5. Financial Analysis
      • 14.2.1.6. Strategic Overview
    • 14.2.2. AstraZeneca plc. (HQ, Business Segments, Employee Strength)
      • 14.2.2.1. Company Details
      • 14.2.2.2. Company Description
      • 14.2.2.3. Business Overview
      • 14.2.2.4. SWOT Analysis
      • 14.2.2.5. Strategic Overview
    • 14.2.3. Merck 7 Co., Inc. (HQ, Business Segments, Employee Strength)
      • 14.2.3.1. Company Details
      • 14.2.3.2. Company Description
      • 14.2.3.3. Business Overview
      • 14.2.3.4. SWOT Analysis
      • 14.2.3.5. Strategic Overview
    • 14.2.4. AbbVie, Inc. (HQ, Business Segments, Employee Strength)
      • 14.2.4.1. Company Details
      • 14.2.4.2. Company Description
      • 14.2.4.3. Business Overview
      • 14.2.4.4. SWOT Analysis
      • 14.2.4.5. Strategic Overview
    • 14.2.5. Valeant Pharmaceuticals International, Inc. (HQ, Business Segments, Employee Strength)
      • 14.2.5.1. Company Details
      • 14.2.5.2. Company Description
      • 14.2.5.3. Business Overview
      • 14.2.5.4. SWOT Analysis
      • 14.2.5.5. Financial Analysis
      • 14.2.5.6. Strategic Overview
    • 14.2.6. GlaxoSmithKline plc. (HQ, Business Segments, Employee Strength)
      • 14.2.6.1. Company Details
      • 14.2.6.2. Company Description
      • 14.2.6.3. Business Overview
      • 14.2.6.4. SWOT Analysis
      • 14.2.6.5. Financial Analysis
      • 14.2.6.6. Strategic Overview
    • 14.2.7. ReViral Ltd. (HQ, Business Segments, Employee Strength)
      • 14.2.7.1. Company Details
      • 14.2.7.2. Company Description
      • 14.2.7.3. Business Overview
      • 14.2.7.4. SWOT Analysis
      • 14.2.7.5. Financial Analysis
      • 14.2.7.6. Strategic Overview
    • 14.2.8. Gilead Sciences, Inc. (HQ, Business Segments, Employee Strength)
      • 14.2.8.1. Company Details
      • 14.2.8.2. Company Description
      • 14.2.8.3. Business Overview
      • 14.2.8.4. SWOT Analysis
      • 14.2.8.5. Financial Analysis
      • 14.2.8.6. Strategic Overview
    • 14.2.9. MEDIVIR AB (HQ, Business Segments, Employee Strength)
      • 14.2.9.1. Company Details
      • 14.2.9.2. Company Description
      • 14.2.9.3. Business Overview
      • 14.2.9.4. SWOT Analysis
      • 14.2.9.5. Strategic Overview
    • 14.2.10. Teva Pharmaceuticals Industries Ltd. (HQ, Business Segments, Employee Strength)
      • 14.2.10.1. Company Details
      • 14.2.10.2. Company Description
      • 14.2.10.3. Business Overview
      • 14.2.10.4. SWOT Analysis
      • 14.2.10.5. Strategic Overview

List of Tables

  • Table 01: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type/Vaccine, 2015-2025
  • Table 02: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form 2015-2025
  • Table 03: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel 2015-2025
  • Table 04: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Region, 2015-2025
  • Table 05: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 06: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015-2025
  • Table 07: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015-2025
  • Table 08: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 09: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/ Sub-Region, 2015-2025
  • Table 10: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015-2025
  • Table 11: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015-2025
  • Table 12: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 13: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 14: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015-2025
  • Table 15: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015-2025
  • Table 16: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 17: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 18: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015-2025
  • Table 19: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015-2025
  • Table 20: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 21: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub Region, 2015-2025
  • Table 22: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015-2025
  • Table 23: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015-2025
  • Table 24: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025a

List of Figures

  • Figure 01: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017-2025
  • Figure 02: Global Respiratory Syncytial virus (RSV) Therapeutics Market Value Share, by Type of Drugs/Vaccine (2016)
  • Figure 03: Global Respiratory Syncytial virus (RSV) Therapeutics Market Value Share, by Dosage Form (2016)
  • Figure 04: Global Respiratory Syncytial virus (RSV) Therapeutics Market Value Share, by Distribution Channel (2016)
  • Figure 05: Global Respiratory Syncytial Virus (RSV) Therapeutics Market, by Drug Type/Vaccine, 2016 and 2025
  • Figure 06: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Drug Type/Vaccine: Palivizumab, 2015-2025
  • Figure 07: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Drug Type/Vaccine: Ribavirin, 2015-2025
  • Figure 08: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Drug Type/Vaccine: Others, 2015-2025
  • Figure 09: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type/Vaccine, 2017-2025
  • Figure 10: Global Respiratory Syncytial Virus (RSV) Therapeutics Market, by Dosage Form, 2016 and 2025
  • Figure 11: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dosage Form: Oral, 2015-2025
  • Figure 12: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dosage Form: Injectable, 2015-2025
  • Figure 13: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dosage Form: Others, 2015-2025
  • Figure 14: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Dosage Form, 2017-2025
  • Figure 15: Global Respiratory Syncytial Virus (RSV) Therapeutics Market, by Distribution Channel, 2016 and 2025
  • Figure 16: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Drug Stores and Retail Pharmacies, 2015-2025
  • Figure 17: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Hospital Pharmacies 2015-2025
  • Figure 18: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Others, 2015-2025
  • Figure 19: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Distribution Channel, 2017-2025
  • Figure 20: Global Respiratory syncytial virus (RSV) Therapeutics Market Value Share, by Region, 2016 and 2025
  • Figure 21: Respiratory Syncytial virus (RSV) Therapeutics Market Attractiveness Analysis, by Region, 2016-2024
  • Figure 22: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 23: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country, 2017 and 2025
  • Figure 24: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country, 2017-2025
  • Figure 25: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
  • Figure 26: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017-2025
  • Figure 27: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
  • Figure 28: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017-2025
  • Figure 29: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
  • Figure 30: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 31: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 32: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country/Sub-Region, 2016 and 2025
  • Figure 33: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country/Sub-Region, 2017-2025
  • Figure 34: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
  • Figure 35: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017-2025
  • Figure 36: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
  • Figure 37: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017-2025
  • Figure 38: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
  • Figure 39: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 40: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 41: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country, 2016 and 2025
  • Figure 42: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country, 2017-2025
  • Figure 43: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
  • Figure 44: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017-2025
  • Figure 45: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
  • Figure 46: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017-2025
  • Figure 47: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
  • Figure 48: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 49: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 50: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country, 2016 and 2025
  • Figure 51: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country, 2017-2025
  • Figure 52: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
  • Figure 53: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017-2025
  • Figure 54: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
  • Figure 55: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017-2025
  • Figure 56: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
  • Figure 57: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 58: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 59: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country/Sub Region, 2016 and 2025
  • Figure 60: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country/Sub Region, 2017-2025
  • Figure 61: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
  • Figure 62: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drugs Type, 2017-2025
  • Figure 63: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
  • Figure 64: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017-2025
  • Figure 65: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
  • Figure 66: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 67: Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 68: R&D Intensity (US$ Bn), 2015-2016
  • Figure 69: Breakdown of Net Sales of Diabetes Care Business Area, by Region 2016
  • Figure 70: Breakdown of Net Sales, by Diagnostic Division, 2016
  • Figure 71: Breakdown of Net Sales, by Region, 2017 (%)
  • Figure 72: R&D Intensity and Sales & Marketing Intensity - Company Level, (US$ Bn), 2016-2017
  • Figure 73: Revenue (US$ Bn) & Y-o-Y Growth (%), 2014-2017
  • Figure 74: Breakdown of Net Sales, (by Business Segment), 2017
  • Figure 75: Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 76: R&D Intensity and Sales & Marketing Intensity - Company Level, 2015-2016
  • Figure 77: Breakdown of Net Sales, by Region (Company Level), 2016
  • Figure 78: Breakdown of Net Sales, (Overall Company Level), 2016
  • Figure 79: Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 80: Breakdown of Net Sales, by Region, 2016